Q&AI think the Q&A was a positive experience for the shareholders as well as the management and we agreed to continue with the meetings on a quarterly cadence.
This Q&A focused on the business, the area that raises most concerns. An upcming meeting will focus on the sciemce with Geraldine. I'm sure it will be interesting even though I totally trust her acrions.
Maybe the very existance of Q&A was the most valuable outcome, the willingness to interact with us directly. This will minimize speculations, build trust and support the share price in the long run.
Naturally the mangement know the details of the AbbVie deal and Howard stated that the company currently is (way) undervalued. I think that we should trade above 40 cents, but that's just my opinion.
PRC seems to be kicked out as a partner for communication. My interpretation is that they have been way into the grey zone and more or less misleading the market.
The alternative to communicating timelines that often are revised due to third party is not communicating at all. I prefer to be on the know and get disappointed from to time, buy maybe the market cannot handle this and thereby affect the shareprice downwards.
Ongoing due diligence related to diabetes and hard to predict timeline, but a deal might not be too far away and thereby avoid the alternative 2 per cent dilution.
Looks like the next 2-3 months will be busy with results from anti-aging and anti-viral and possibly two diabetes deals.
I'm more positive to the company compared to pre-Q&A.